ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "hypertension"

  • Abstract Number: 2370 • 2017 ACR/ARHP Annual Meeting

    Endothelial Nitric Oxide Synthase Gene Polymorphism As a Risk Factor of Hypertension in Patients with Rheumatoid Arthritis

    Mykola Stanislavchuk1,2, Kateryna Zaichko2 and Ayad Sulaiman2, 1Internal Medicine, VNMU n.a. M. Pirogov, Vinnytsia, Ukraine, 2Rheumatology, Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine

    Background/Purpose: Rheumatoid arthritis (RA) and hypertension (HT) are multifactorial polygenic diseases. The incidence of hypertension in patients with RA is higher than in the general…
  • Abstract Number: 670 • 2017 ACR/ARHP Annual Meeting

    Membrane Attack Complex (MAC) Deposition in Lupus Nephritis Is Associated with Hypertension and Poor Clinical Response to Treatment

    Shudan Wang1, Ming Wu2, Luis Chiriboga3, Briana Zeck4 and H. Michael Belmont5, 1Department of Medicine, Division of Rheumatology, New York University School Medicine, New York City, NY, 2New York University School of Medicine, New York, NY, 3Pathology, New York University School Medicine, New York, NY, 4Pathology, New York University School Medicine, New York City, NY, 5Medicine, New York University School of Medicine, New York, NY

    Background/Purpose: LN is characterized by deposition of immune complexes in the kidney. Activation of the classical complement pathway by dsDNA is believed to play a…
  • Abstract Number: 1088 • 2017 ACR/ARHP Annual Meeting

    Staff Protocol in Rheumatology Clinics Reduces Population-Level Rate of High Blood Pressure

    Christie M. Bartels1, Edmond Ramly2, Emmanuel Sampene3, Diane Lauver4, Patrick McBride5 and Heather Johnson5, 1Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, 2Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, 3Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, 4University of Wisconsin-Madison School of Nursing, Madison, WI, 5Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: The Centers for Disease Control and Prevention director has said “nothing will save more lives” than protocols to control blood pressure (BP). BP is…
  • Abstract Number: 1267 • 2017 ACR/ARHP Annual Meeting

    Blood Pressure Control over Time in Childhood-Onset Systemic Lupus Erythematous

    Pinar Ozge Avar Aydin1, Jian Shan2, Hermine I. Brunner1 and Mark Mitsnefes3, 1Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Peking Union Medical College Hospital, Peking, China, Peking, China, 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Cardiovascular disease (CVD) is the leading cause of increased long-term morbidity and mortality in systemic lupus erythematosus (SLE). As an important modifiable risk factor…
  • Abstract Number: 23 • 2016 ACR/ARHP Annual Meeting

    Incidence of Non Alcoholic Fatty Liver Disease By Key Risk Factors Among Patients with Rheumatoid Arthritis

    Ani John1, Angela Witt Prehn2, Hebatullah Tawfik2, George W. Reed3 and Joel Kremer4, 1School of Health Sciences, Walden University, Minneapolis, CA, 2School of Health Sciences, Walden University, Minneapolis, MN, 3Corrona, LLC, Southborough, MA, 4The Center for Rheumatology, Albany Medical College, Albany, NY

    Background/Purpose: The prevalence and characteristics of patients with nonalcoholic fatty liver disease (NAFLD) have not been well characterized in the RA population. The purpose of…
  • Abstract Number: 397 • 2016 ACR/ARHP Annual Meeting

    Comorbidities Associated with Pediatric Psoriatic Arthritis

    Cynthia Manos1, Rui Xiao2, Alexis Ogdie3, Timothy Brandon4 and Pamela F. Weiss5,6, 1Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA, 4Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, 5Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 6Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: In adults, psoriatic arthritis (PsA) is associated with an increased prevalence of obesity, hypertension, and diabetes.  It is not yet known if pediatric patients…
  • Abstract Number: 412 • 2016 ACR/ARHP Annual Meeting

    Oral Glucocorticoids and Rates of Incident Diabetes Mellitus and Hypertension in Children with Juvenile Idiopathic Arthritis and Attention-Deficit/Hyperactivity Disorder

    Daniel B. Horton1, Fenglong Xie2, Lang Chen2, Melissa Mannion3, Brian L. Strom4,5, Jeffrey Curtis6 and Timothy Beukelman7, 1Pediatrics, Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, 2Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 4Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 5Rutgers Biomedical and Health Sciences, New Brunswick, NJ, 6Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose:  Diabetes mellitus (DM) and hypertension (HTN) are well-known toxicities of glucocorticoids (GCs), but the risks of these complications are unclear in children with JIA.…
  • Abstract Number: 859 • 2016 ACR/ARHP Annual Meeting

    Long-Term Outcomes of Renal Artery Involvement in Takayasu Arteritis

    Seokchan Hong1, Oh Chan Kwon2, Byeongzu Ghang3, Yong-Gil Kim1, Chang-Keun Lee1 and Bin Yoo1, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, The Republic of, 3Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

    Long-term Outcomes of Renal Artery Involvement in Takayasu Arteritis Background/Purpose: Takayasu arteritis (TA) involving the renal artery can result in hypertension, renal dysfunction, and premature…
  • Abstract Number: 973 • 2016 ACR/ARHP Annual Meeting

    Clinical Characterization of Patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort

    Jessica K. Gordon1, Jackie Szymonifka2, Matthew R. Lammi3, Virginia D. Steen4 and PHAROS Investigators, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, 3Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, 4Rheumatology, Georgetown University Medical Center, Washington, DC

    Background/Purpose:  Pulmonary hypertension (PH) is a leading cause of death in patients (pts) with Systemic Sclerosis (SSc). The World Health Organization (WHO) classifies PH into…
  • Abstract Number: 1477 • 2016 ACR/ARHP Annual Meeting

    Exploring the Inadequate Cardiovascular Disease Prevention in Inflammatory Joint Diseases: Results from a Nationwide Norwegian Project

    Eirik Ikdahl1, Silvia Rollefstad2, Grunde Wibetoe3, Anne Salberg4, Dag Magnar Soldal5, Inge C Olsen6, Tore K Kvien7, Anne Grete Semb1 and Glenn Haugeberg8, 1Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Hospital for Rheumatic Diseases, Lillehammer, Norway, 5Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, 6Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 7Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 8Martina Hansens Hospital, Bærum, Norway

    Background/Purpose: Antihypertensives (antiHT) and lipid lowering therapies (LLT) prevent cardiovascular disease (CVD) effectively. It has been reported that patients with rheumatoid arthritis (RA) receive suboptimal…
  • Abstract Number: 1481 • 2016 ACR/ARHP Annual Meeting

    Success Rate of Blood Pressure Goal Achievement in Patients with Inflammatory Joint Diseases

    Silvia Rollefstad, Pia Norheim, Eirik Ikdahl and Anne Grete Semb, Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: The excess risk of cardiovascular disease (CVD) in patients with inflammatory joint diseases (IJD) is attributable to several risk factors, including a high prevalence…
  • Abstract Number: 2051 • 2016 ACR/ARHP Annual Meeting

    Risk Factors for Cardiovascular Disease Predate the Onset of Symptoms of Rheumatoid Arthritis

    Heidi Kokkonen1, Lisbeth Ärlestig2 and Solbritt Rantapää-Dahlqvist3,4, 1Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, 2Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 3Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, 4Rheumatology, Umeå University, Umeå, Sweden

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular (CV) comorbidity compared with the general population. Contradictory results concerning CV disease…
  • Abstract Number: 2161 • 2016 ACR/ARHP Annual Meeting

    Association Between Inflammation and Systolic Blood Pressure at Normal and High C-Reactive Protein Levels

    Zhi Yu1, Kathleen Vanni2, Seoyoung C. Kim3, Daniel H. Solomon4, Shawn N. Murphy5 and Katherine Liao6, 1Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Research Computing, Partners Healthcare Systems, Boston, MA, 6Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: While inflammation is linked with higher blood pressure (BP) in the general population, few studies have examined this relationship in patients with elevated levels…
  • Abstract Number: 2171 • 2016 ACR/ARHP Annual Meeting

    Increased Rates of Hypertension in Patients with Psoriatic Arthritis Compared to Psoriasis Alone: Results from the UK Biobank

    Eftychia Bellou1, Suzanne M.M. Verstappen2, Michael Cook3, Jamie C Sergeant3,4, Richard B. Warren5, Anne Barton1,4 and John Bowes1, 1Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK, Manchester, United Kingdom, 2Centre for Musculoskeletal Research, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, 4NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 5Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with the presence of psoriasis. Both conditions are influenced by lifestyle factors such as alcohol…
  • Abstract Number: 2287 • 2016 ACR/ARHP Annual Meeting

    Serum Urate and Its Association with Endothelial Dysfunction in Young Adults

    Michael B. Saddekni1, Kenneth G. Saag1, Tanja Dudenbostel2, Suzanne Oparil2, David A. Calhoun2, Daniel I. Feig3, Paul M. Muntner4, David T. Redden5, Phillip J. Foster1, Elizabeth J. Rahn1, Stephanie R. Biggers1, Peng Li5 and Angelo L. Gaffo1, 1Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, 3Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 4Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 5Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Both serum urate (sUA) and endothelial dysfunction have been associated with hypertension and cardiovascular disease. Increasing sUA level has been associated with endothelial dysfunction…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology